Wall Street brokerages forecast that Nuvectra Corp (NASDAQ:NVTR) will announce ($0.86) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Nuvectra’s earnings, with estimates ranging from ($0.91) to ($0.80). Nuvectra posted earnings of ($1.09) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 21.1%. The firm is scheduled to announce its next earnings report on Wednesday, November 7th.

On average, analysts expect that Nuvectra will report full year earnings of ($3.44) per share for the current financial year, with EPS estimates ranging from ($3.62) to ($3.25). For the next financial year, analysts expect that the business will report earnings of ($2.51) per share, with EPS estimates ranging from ($2.83) to ($2.18). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Nuvectra.

Nuvectra (NASDAQ:NVTR) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.11. Nuvectra had a negative net margin of 98.28% and a negative return on equity of 77.95%. The firm had revenue of $13.15 million during the quarter, compared to the consensus estimate of $11.57 million.

A number of equities analysts recently weighed in on NVTR shares. BidaskClub raised shares of Nuvectra from a “hold” rating to a “buy” rating in a research note on Saturday, August 18th. ValuEngine raised shares of Nuvectra from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. SunTrust Banks lifted their target price on shares of Nuvectra to $27.00 and gave the stock a “buy” rating in a research note on Thursday, June 21st. Zacks Investment Research downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a research note on Thursday, May 17th. Finally, JMP Securities lifted their target price on shares of Nuvectra from $18.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $23.50.

NASDAQ NVTR traded up $0.07 during mid-day trading on Friday, reaching $22.76. 342 shares of the stock were exchanged, compared to its average volume of 205,616. Nuvectra has a one year low of $7.60 and a one year high of $23.79. The company has a market capitalization of $321.86 million, a PE ratio of -5.39 and a beta of -1.76. The company has a quick ratio of 3.77, a current ratio of 4.10 and a debt-to-equity ratio of 0.75.

In other Nuvectra news, President Joseph Paul Hanchin sold 1,250 shares of Nuvectra stock in a transaction on Monday, August 20th. The shares were sold at an average price of $20.43, for a total value of $25,537.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of NVTR. Wells Fargo & Company MN increased its stake in Nuvectra by 97.1% in the first quarter. Wells Fargo & Company MN now owns 251,629 shares of the company’s stock valued at $3,276,000 after purchasing an additional 123,964 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in shares of Nuvectra during the first quarter valued at about $5,593,000. JPMorgan Chase & Co. grew its holdings in shares of Nuvectra by 1,053.5% during the first quarter. JPMorgan Chase & Co. now owns 19,309 shares of the company’s stock valued at $251,000 after buying an additional 17,635 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Nuvectra during the first quarter valued at about $2,700,000. Finally, Tibra Equities Europe Ltd acquired a new position in shares of Nuvectra during the first quarter valued at about $400,000. 74.22% of the stock is owned by hedge funds and other institutional investors.

Nuvectra Company Profile

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.

Further Reading: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.